Profound Medical (TSX:PRN) LT-Debt-to-Total-Asset: 0.04 (As of Mar. 2026)

What is Profound Medical LT-Debt-to-Total-Asset?

Profound Medical TSX:PRN +7.28% 68 LT-Debt-to-Total-Asset is 0.04 as of Mar. 2026. GuruFocus rates TSX:PRN with a GF Score™ of 68/100 and a GF Value™ of C$20.37 (Possible Value Trap). The stock has 1 warning sign investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Profound Medical's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.04.

Profound Medical's long-term debt to total assets ratio declined from Mar. 2025 (0.08) to Mar. 2026 (0.04). It may suggest that Profound Medical is progressively becoming less dependent on debt to grow their business.

Profound Medical (TSX:PRN) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Profound Medical LT-Debt-to-Total-Asset Related Terms

Profound Medical LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Profound Medical's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Profound Medical LT-Debt-to-Total-Asset Chart

Profound Medical Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.01

0.12

0.13

0.05

0.06

Profound Medical Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.08	0.09	0.00	0.06	0.04

68GF Score

Profound Medical Corp TSX:PRN

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Profound Medical LT-Debt-to-Total-Asset Calculation

Profound Medical's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	6.206	/	106.877
	=	0.06

Profound Medical's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	3.968	/	100.782
	=	0.04

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.04 mean?

Profound Medical (TSX:PRN) has a LT-Debt-to-Total-Asset of 0.04 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Profound Medical and its competitors.

Is Profound Medical's LT-Debt-to-Total-Asset too high?

Profound Medical's current LT-Debt-to-Total-Asset is 0.04. Overall, Profound Medical has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does Profound Medical's LT-Debt-to-Total-Asset compare to ABT and SYK?

Profound Medical's LT-Debt-to-Total-Asset of 0.04 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Medical Devices & Instruments company?

A good LT-Debt-to-Total-Asset depends on the Medical Devices & Instruments industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Profound Medical and its competitors. Profound Medical's current LT-Debt-to-Total-Asset is 0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Profound Medical stock overvalued right now?

Based on GuruFocus' analysis, Profound Medical (TSX:PRN) is currently considered Possible Value Trap. The stock's GF Value™ is C$20.37, compared to a current price of C$10.46 — trading 48.6% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.04. Profound Medical's overall GF Score™ is 68/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Profound Medical (TSX:PRN), the current LT-Debt-to-Total-Asset is 0.04 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Profound Medical (TSX:PRN) Overvalued in 2026?

Based on GuruFocus' analysis, Profound Medical stock appears to be undervalued. The current stock price of C$10.46 is trading 48.6% below its estimated GF Value™ of C$20.37. GuruFocus considers Profound Medical to be Possible Value Trap.

Key valuation signals for TSX:PRN:

LT-Debt-to-Total-Asset: 0.04
GF Value™: C$20.37 vs. price of C$10.46 (48.6% below fair value)
GF Score™: 68/100 with 1 warning sign

No single metric tells the full story. See the TSX:PRN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Profound Medical Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies TSXV:TLT XCNQ:BLO XCNQ:VIVI TSXV:PINK TSXV:CHER TSXV:CNVI TSXV:VPT TSXV:ASG TSXV:MDX TSXV:VVTM ABT SYK MDT BSX EW XTER:SHL GEHC DXCM XAMS:PHIA SZSE:300760

Other Exchanges PROF:USA

Address 2400 Skymark Avenue, Unit 6, Mississauga, ON, CAN, L4W 5K5

Website https://www.profoundmedical.com

Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.

68GF Score

Get the complete analysis for TSX:PRN

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$10.46

Price

C$20.37

GF Value

View TSX:PRN Analysis

See LT-Debt-to-Total-Asset data for all stocks →